RS51135B - Formulacija suspenzije feksofenadina - Google Patents

Formulacija suspenzije feksofenadina

Info

Publication number
RS51135B
RS51135B RSP-2009/0360A RSP20090360A RS51135B RS 51135 B RS51135 B RS 51135B RS P20090360 A RSP20090360 A RS P20090360A RS 51135 B RS51135 B RS 51135B
Authority
RS
Serbia
Prior art keywords
water
expressed
mass
volume
pharmaceutical suspension
Prior art date
Application number
RSP-2009/0360A
Other languages
English (en)
Serbian (sr)
Inventor
Prafulla Agrawala
Kazimierz Chrzan
Rajiv Haribhakti
Matthew Mermey
Curtis J. Porcello
Gary Lee Silvey
Vinh Tran
Original Assignee
Sanofi-Aventis U.S. Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51135(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi-Aventis U.S. Llc filed Critical Sanofi-Aventis U.S. Llc
Publication of RS51135B publication Critical patent/RS51135B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
RSP-2009/0360A 2005-12-14 2006-12-12 Formulacija suspenzije feksofenadina RS51135B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14
PCT/US2006/047393 WO2007070517A2 (en) 2005-12-14 2006-12-12 Fexofenadine suspension formulation

Publications (1)

Publication Number Publication Date
RS51135B true RS51135B (sr) 2010-10-31

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0360A RS51135B (sr) 2005-12-14 2006-12-12 Formulacija suspenzije feksofenadina

Country Status (38)

Country Link
US (1) US8933097B2 (OSRAM)
EP (1) EP1965768B1 (OSRAM)
JP (1) JP5308824B2 (OSRAM)
KR (1) KR101452792B1 (OSRAM)
CN (1) CN101316580B (OSRAM)
AR (1) AR058323A1 (OSRAM)
AT (1) ATE431137T1 (OSRAM)
AU (1) AU2006326551B2 (OSRAM)
BR (1) BRPI0619895B1 (OSRAM)
CA (1) CA2633086C (OSRAM)
CR (1) CR9993A (OSRAM)
CY (1) CY1109320T1 (OSRAM)
DE (1) DE602006006870D1 (OSRAM)
DK (1) DK1965768T3 (OSRAM)
DO (1) DOP2006000274A (OSRAM)
EC (1) ECSP088532A (OSRAM)
EG (1) EG25866A (OSRAM)
ES (1) ES2327168T3 (OSRAM)
HN (1) HN2008000875A (OSRAM)
HR (1) HRP20090411T1 (OSRAM)
IL (1) IL192067A (OSRAM)
JO (1) JO2549B1 (OSRAM)
MA (1) MA30152B1 (OSRAM)
MY (1) MY146988A (OSRAM)
NO (1) NO339877B1 (OSRAM)
NZ (1) NZ568943A (OSRAM)
PE (1) PE20071003A1 (OSRAM)
PL (1) PL1965768T3 (OSRAM)
PT (1) PT1965768E (OSRAM)
RS (1) RS51135B (OSRAM)
RU (1) RU2405538C2 (OSRAM)
SI (1) SI1965768T1 (OSRAM)
TN (1) TNSN08186A1 (OSRAM)
TW (1) TWI377061B (OSRAM)
UA (1) UA89584C2 (OSRAM)
UY (1) UY30021A1 (OSRAM)
WO (1) WO2007070517A2 (OSRAM)
ZA (1) ZA200803985B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
WO2013058996A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
JP6410814B2 (ja) 2013-07-01 2018-10-24 アベンティスユービー・エルエルシー フェキソフェナジンを含む経口投与用液体医薬組成物
CN105358138A (zh) * 2013-07-03 2016-02-24 R.P.谢勒技术有限公司 包含非索非那定的胶囊制剂
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
CN109906079B (zh) * 2016-06-16 2022-09-30 库蒂斯制药公司 用于质子泵抑制剂混悬剂的组合物和方法
JP7169671B2 (ja) 2017-06-02 2022-11-11 テイカ製薬株式会社 難水溶性成分可溶化ミセル及びそれを含有する液剤
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
WO2022038474A1 (en) * 2020-08-18 2022-02-24 Innate S.R.L. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
US20250082623A1 (en) * 2021-12-29 2025-03-13 Opella Healthcare Group Sas Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
CR20240566A (es) * 2023-01-20 2025-02-25 Opella Healthcare Group Sas Formulaciones de fexofenadina sin parabenos
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
CA2449419C (en) 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
DE60225694T2 (de) 2001-07-31 2008-06-26 Texcontor Etablissement Neues polymorph von fexo-fenadin
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
EP1587496B1 (en) * 2003-01-30 2009-10-07 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
DK2486942T3 (en) * 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
AU2006278874A1 (en) 2005-07-27 2007-02-15 Sandoz Ag A process for the preparation of substituted phenyl ether compounds and rosiglitazone
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物

Also Published As

Publication number Publication date
NO339877B1 (no) 2017-02-13
EP1965768B1 (en) 2009-05-13
AU2006326551B2 (en) 2012-06-07
JO2549B1 (en) 2010-09-05
MY146988A (en) 2012-10-15
JP2009519935A (ja) 2009-05-21
ZA200803985B (en) 2009-03-25
BRPI0619895A2 (pt) 2011-10-25
DE602006006870D1 (de) 2009-06-25
EG25866A (en) 2012-09-12
AR058323A1 (es) 2008-01-30
KR20080074180A (ko) 2008-08-12
CA2633086C (en) 2011-10-18
HN2008000875A (es) 2012-01-30
HRP20090411T1 (hr) 2010-01-31
JP5308824B2 (ja) 2013-10-09
WO2007070517A2 (en) 2007-06-21
UY30021A1 (es) 2007-07-31
NO20082904L (no) 2008-09-10
TWI377061B (en) 2012-11-21
CR9993A (es) 2008-09-23
PE20071003A1 (es) 2007-10-03
KR101452792B1 (ko) 2014-10-22
CN101316580A (zh) 2008-12-03
IL192067A0 (en) 2009-02-11
BRPI0619895B1 (pt) 2022-04-12
US8933097B2 (en) 2015-01-13
WO2007070517A3 (en) 2007-08-23
UA89584C2 (en) 2010-02-10
ES2327168T3 (es) 2009-10-26
AU2006326551A1 (en) 2007-06-21
ECSP088532A (es) 2008-08-29
CA2633086A1 (en) 2007-06-21
PT1965768E (pt) 2009-08-07
DOP2006000274A (es) 2007-10-15
NZ568943A (en) 2010-04-30
TNSN08186A1 (en) 2009-10-30
PL1965768T3 (pl) 2009-11-30
IL192067A (en) 2010-12-30
CY1109320T1 (el) 2014-07-02
ATE431137T1 (de) 2009-05-15
CN101316580B (zh) 2011-11-16
DK1965768T3 (da) 2009-09-07
US20080299211A1 (en) 2008-12-04
EP1965768A2 (en) 2008-09-10
MA30152B1 (fr) 2009-01-02
TW200812581A (en) 2008-03-16
HK1123197A1 (en) 2009-06-12
RU2008128418A (ru) 2010-01-20
SI1965768T1 (sl) 2009-10-31
RU2405538C2 (ru) 2010-12-10

Similar Documents

Publication Publication Date Title
US8933097B2 (en) Fexofenadine suspension formulation
JP3441676B2 (ja) ジプラシドン組成物
EP2271612B1 (en) Rasagiline mesylate particles and process for the preparation thereof
Herbrink et al. Solubility and bioavailability improvement of pazopanib hydrochloride
Jagadish et al. Enhanced dissolution and bioavailability of raloxifene hydrochloride by co-grinding with different superdisintegrants
CN114099512B (zh) 卡利拉嗪药物组合物、制备方法及应用
US10085991B2 (en) Formulation inhibiting effects of low acid environment
HK1123197B (en) Fexofenadine suspension formulation
HK135494A (en) Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient
US20040142903A1 (en) Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
WO2025242585A1 (en) Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2020136093A1 (en) Process for preparing spherical agglomerates of timapiprant
CN115337276A (zh) 一种新型的枸橼酸西地那非口腔崩解组合物